- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03859531
Gastrointestinal Study at Orkambi Therapy in CF Patients
Gastrointestinal Outcome Measures Before and After Orkambi Therapy in Cystic Fibrosis (CF) Patients Carrying the F508del Mutation on Both Alleles
Studieoversikt
Status
Forhold
Detaljert beskrivelse
To examine the entire intestinal mucosa via capsule endoscopy before and 6 months after Orkambi therapy to ascertain if the inflammatory changes in the intestine have improved. A marker of intestinal inflammation measured in the stool, Calprotectin, will be examined before and 6 months after Orkambi treatment. The investigators hypothesize that the result will be reduced on therapy.
A marker of pancreatic exocrine function, pancreatic elastase, will be examined before and 6 months after therapy to examine if the result has increased indicating improvement of exocrine pancreatic function
Study Population All subjects with CF homozygous for the F508del mutation in Sweden eligible for Orkambi therapy, i.e. above 12 years of age, in total 145 patients in Sweden of which 60 are taken care of at Stockholm CF Center; the investigators aim to examine 20 patients.
Study Duration The duration will be 6 months for each patient.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Stockholm, Sverige, 14186
- Rekruttering
- Stockholm CF center
-
Ta kontakt med:
- Isabelle de Monestrol, MD PhD
- Telefonnummer: +468 58580000
- E-post: isabelle.demonestrol@ki.se
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- CF patients F508del homozygote
- >12 years of age
- eligible for Orkambi therapy.
Exclusion Criteria:
- Patients who the patency capsule does not pass within 48 hrs
- FEV1<30%
- Pregnancy and breastfeeding women
- Liver function blood tests (AST, ALT, Gamma-GT, ALP) >3 xULN
- Bilirubin >2 xULN
- AST or ALT alone >5 xULN
- Previous lung transplant
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
CF patients planned to receive Orkambi
CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Concentration of fecal calprotectin
Tidsramme: Change from baseline at 6 months after commencing treatment with Orkambi
|
Is a marker of intestinal inflammation measured in the stool
|
Change from baseline at 6 months after commencing treatment with Orkambi
|
Concentration of fecal elastase-1
Tidsramme: Change from baseline at 6 months after commencing treatment with Orkambi
|
Is a test of pancreatic function measured in the stool.
|
Change from baseline at 6 months after commencing treatment with Orkambi
|
Change in small bowel capsule endoscopy (SBCE)
Tidsramme: Change from baseline at 6 months after commencing treatment with Orkambi
|
The method of SBCE has been well established as a descriptive diagnostic tool for intestinal inflammation and has been used as an outcome measure in clinical trials.
Erythema, petechiae, mucosal erosions and ulcerations will be assessed according to the Maiden criteria
|
Change from baseline at 6 months after commencing treatment with Orkambi
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in CRP
Tidsramme: Change from baseline at 6 months after commencing treatment with Orkambi
|
Inflammatory marker, unit mg/L.
|
Change from baseline at 6 months after commencing treatment with Orkambi
|
Change in sedimentation rate
Tidsramme: Change from baseline at 6 months after commencing treatment with Orkambi
|
Inflammatory marker, unit mm.
|
Change from baseline at 6 months after commencing treatment with Orkambi
|
Concentration of serum electrophoresis.
Tidsramme: Change from baseline, 6 months after commencing treatment with Orkambi
|
Inflammatory markers: alpha-1-antitrypsin, haptoglobin, orosomucoid, immunoglobulin A, M and G.
|
Change from baseline, 6 months after commencing treatment with Orkambi
|
Change in liver function tests
Tidsramme: Change from baseline at 6 months after commencing treatment with Orkambi
|
ALT, AST, ALP, gamma-GT.
Unit: mikrokat/L
|
Change from baseline at 6 months after commencing treatment with Orkambi
|
Change in bilirubin
Tidsramme: Change from baseline at 6 months after commencing treatment with Orkambi
|
Bilirubin. Unit: mikromol/L
|
Change from baseline at 6 months after commencing treatment with Orkambi
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Isabelle de Monestrol, MD PhD, Stockholm CF center
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466. No abstract available.
- Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, Schwarzenberg SJ. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Dig Dis Sci. 2016 Jan;61(1):198-207. doi: 10.1007/s10620-015-3834-2. Epub 2015 Aug 7.
- Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, Malka N, Cohen L, Armoni S, Yatzkan-Israelit Y, Bergwerk A, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, Wilschanski M. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):304-8. doi: 10.1097/MPG.0b013e3181d1b013.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CF-GI-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Cystisk fibrose
-
National Institute of Allergy and Infectious Diseases...Fullført